Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best biotech stocks with high potential. H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM) on September 15, retaining the price target of $80.
The analyst supported the optimistic rating with the company’s strong momentum in its in vivo and ex vivo base editing programs.
Similarly, in a report released on September 10, Kostas Biliouris from BMO Capital also maintained a Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM) and set a price target of $40.00.
Biliouris supported the optimistic rating with the company’s technological advancements and strong position in the AATD market, adding that management’s confidence in the competitive positioning of BEAM-302 is a crucial reason for the bullish stance.
Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that develops precision genetic medicines through base editing, a technology that allows efficient and predictable single-base changes at targeted genomic sequences. The company’s lead programs focus on sickle cell disease and alpha-1 antitrypsin deficiency.
Beam Therapeutics Inc. (NASDAQ:BEAM) is advancing programs in other genetic diseases as well, along with oncology and immunology.
While we acknowledge the potential of BEAM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
